Jeffrey D. Capello has made significant moves in his investment in Neogen Corporation, as disclosed in a recent filing. On October 2, 2026, Capello reported the acquisition of 9,804 restricted stock units and 20,558 common stock options. This transaction is noteworthy as it indicates Capello's increasing stake in Neogen, a company known for its work in the life sciences sector.
Neogen Corporation, which operates under the ticker symbol NEOG, specializes in in vitro and in vivo diagnostic substances. The company, based in Lansing, Michigan, has been a key player in the life sciences industry, focusing on innovative solutions for food and animal safety.
The filing details that Capello's transaction occurred on October 1, 2026. The restricted stock units were acquired at a price of $12.24 per share, while the common stock options were obtained at no cost, with a conversion price also set at $12.24. Following the transactions, Capello now holds a total of 42,306 shares in Neogen.
This update may affect various stakeholders, including Neogen's management team, employees, and shareholders. Capello's increased ownership could signal confidence in the company's future performance and strategic direction. The filing, identified by accession number 0000711377-26-000022, underscores the ongoing commitment of key individuals to the growth of Neogen.
As of now, the filing does not specify any upcoming actions or additional filings related to this transaction.